CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Novartis to pay $125M for blood-brain barrier crossing platform

Positive
AI Analysis

Summary

Novartis acquires Sironax's blood-brain barrier crossing platform technology for $125M, gaining global rights to advance three candidates with potential best-in-class status.

Importance:7/10
Sentiment:
0.60
M&Aacquisitionblood-brain barrierplatform technologyNovartisSironax
Related Companies

Read the original article

Published by BioPharma Dive on September 16, 2026 8:26 PM

Read Original